Biothom Oy

Biothom Oy is a Finnish private investment firm based in Helsinki, focusing on investments in various areas of life sciences. The firm has interests in young, innovative companies in the United States, Finland, and Sweden. Biothom is a member of Thominvest Group, a privately held Finnish investment firm.

The firm's investment strategy centers on early-stage and growth-stage companies within the biotechnology and healthcare sectors. Biothom has been involved in several notable investments, including a €2.3 million funding round for StemSight, a Tampere-based biotech startup developing stem cell therapies for vision restoration. The funding round was led by Voima Ventures and supported by Finnish family offices, including Biothom Oy, private investors, and Business Finland.

Biothom Oy's portfolio also includes Mendor, a company specializing in innovative diabetes care products and services. In 2010, Biothom participated in a €8.1 million Series B financing round for Mendor, aimed at facilitating its global market expansion. This investment underscores Biothom's commitment to supporting companies that develop groundbreaking solutions in the life sciences sector.

Biothom Oy's approach emphasizes strategic investments in companies with high growth potential, particularly those addressing significant challenges in healthcare and biotechnology. The firm's involvement in these sectors reflects its dedication to fostering innovation and advancing medical technologies that can have a meaningful impact on global health.